Linda K Rushworth
Overview
Explore the profile of Linda K Rushworth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rushworth L, Loveridge C, Salji M, MacLeod M, Mui E, Sumpton D, et al.
BJU Int
. 2022 Jul;
131(2):236-243.
PMID: 35844167
Objectives: To test for evidence of statin-mediated effects in patients with castration-resistant prostate cancer (CRPC) as post-diagnosis use of statins in patients with prostate cancer is associated with favourable survival...
2.
Patel R, Ford C, Rodgers L, Rushworth L, Fleming J, Mui E, et al.
Cancer Res
. 2022 Jun;
82(14):2565-2575.
PMID: 35675421
Significance: Enhanced creatine uptake drives prostate cancer progression and confers a metabolic vulnerability to treatment with the creatine analog cyclocreatine.
3.
Kidger A, Saville M, Rushworth L, Davidson J, Stellzig J, Ono M, et al.
Oncogene
. 2022 Apr;
41(20):2811-2823.
PMID: 35418690
The cytoplasmic phosphatase DUSP6 and its nuclear counterpart DUSP5 are negative regulators of RAS/ERK signalling. Here we use deletion of either Dusp5 or Dusp6 to explore the roles of these...
4.
Blomme A, Peter C, Mui E, Blanco G, An N, Mason L, et al.
EMBO Mol Med
. 2022 Jan;
14(3):e14764.
PMID: 35014179
Despite the clinical benefit of androgen-deprivation therapy (ADT), the majority of patients with advanced prostate cancer (PCa) ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we identified thioesterase...
5.
In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer
Rushworth L, Harle V, Repiscak P, Clark W, Shaw R, Hall H, et al.
Life Sci Alliance
. 2020 Oct;
3(12).
PMID: 33033111
Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit because of emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model...
6.
Rushworth L, Hewit K, Munnings-Tomes S, Somani S, James D, Shanks E, et al.
Br J Cancer
. 2019 Dec;
122(4):517-527.
PMID: 31844184
Background: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop combination therapies have not translated into new treatments. We sought to develop a...
7.
Patel R, Brzezinska E, Repiscak P, Ahmad I, Mui E, Gao M, et al.
Cancer Res
. 2019 Nov;
80(3):576-590.
PMID: 31719098
Inhibition of the androgen receptor (AR) is the main strategy to treat advanced prostate cancers. AR-independent treatment-resistant prostate cancer is a major unresolved clinical problem. Patients with prostate cancer with...
8.
Kidger A, Rushworth L, Stellzig J, Davidson J, Bryant C, Bayley C, et al.
Proc Natl Acad Sci U S A
. 2017 Jan;
114(3):E317-E326.
PMID: 28053233
Deregulated extracellular signal-regulated kinase (ERK) signaling drives cancer growth. Normally, ERK activity is self-limiting by the rapid inactivation of upstream kinases and delayed induction of dual-specificity MAP kinase phosphatases (MKPs/DUSPs)....
9.
Rushworth L, Kidger A, Delavaine L, Stewart G, van Schelven S, Davidson J, et al.
Proc Natl Acad Sci U S A
. 2014 Dec;
111(51):18267-72.
PMID: 25489104
Ectopic expression of dual-specificity phosphatase 5 (DUSP5), an inducible mitogen-activated protein (MAP) kinase phosphatase, specifically inactivates and anchors extracellular signal-regulated kinase (ERK)1/2 in the nucleus. However, the role of endogenous...
10.
Kucharska A, Rushworth L, Staples C, Morrice N, Keyse S
Cell Signal
. 2009 Aug;
21(12):1794-805.
PMID: 19666109
DUSP5 is an inducible, nuclear, dual-specificity phosphatase, which specifically interacts with and inactivates the ERK1/2 MAP kinases in mammalian cells. In addition, expression of DUSP5 causes nuclear translocation of ERK2...